Scientists pinpoint potential new target for regulating inflammation

May 07, 2019

Scientists from Trinity College Dublin have discovered a potential new target for regulating inflammation, which drives a range of diseases including diabetes, cancer and Alzheimer's. The potential target is an ancient immune protein - SARM - that has been conserved throughout evolution and thus is very similar in humans, other mammals, flies and worms.

The scientists, from Trinity's School of Biochemistry and Immunology based at the Trinity Biomedical Sciences Institute (TBSI), discovered a previously unknown but important role that SARM plays in the immune response. Their work has been published today in the prestigious journal Immunity.

The innate immune system and SARM

The innate immune system is activated as a protective mechanism in response to cells sensing the presence of strangers such as bacteria and viruses, or of dangers such as tissue injury. This innate immune activation leads to inflammation. However, excessive and/or inappropriate inflammation is implicated in a range of debilitating diseases and so controlling inflammation presents a major problem that scientists are trying to solve.

Specifically, it is inflammasomes - tiny molecular machines - that assemble inside immune cells after sensing infection or injury and initiate the inflammatory response. When assembled, inflammasomes trigger 1) the release of an inflammatory mediator (interleukin-1, or IL-1) and 2) instigate an inflammatory form of cell death (pyroptosis).

Both of these actions can drive inflammation, but what controls the amount of IL-1 produced and the extent of pyroptosis that occurs during inflammation was previously unknown. It turns out that SARM is a key inflammasome regulator.

In their study, the scientists showed that the more SARM that cells contain, the less IL-1 they produce, because SARM interferes with inflammasome assembly. Conversely, more SARM leads to more cell death since SARM causes significant damage to mitochondria, the energy producers of the cell.

The work, which was funded by Science Foundation Ireland, was conducted by scientists in Professor Andrew Bowie's research group, in particular co-first authors Dr Michael Carty and Dr Jay Kearney. Other TBSI scientists involved include Professors Ed Lavelle and Padraic Fallon.

Dr Michael Carty, lead author of the study, said: ''We've been working to try to unlock the secrets of what this ancient protein does for some time, and it was a surprise to find that it could be a key regulator of the inflammasome, which may implicate SARM in inflammatory diseases."

Professor of Innate Immunology at Trinity, Andrew Bowie, added: "Scientists already knew that SARM drives cell death in the brain, and as a result it is being investigated as a therapeutic target for neurodegeneration and related diseases, but here we found that it is also a key immune regulator in peripheral immune cells. This discovery gives us hope that if we can successfully target SARM we may be able to regulate inflammation, which would provide a new option for treating a plethora of diseases."
-end-


Trinity College Dublin

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.